Antibody ligation of CM1 on cisplatin-exposed HeLa cells induces apoptosis through reactive oxygen species-dependent Fas ligand expression

Park,Ga Bin; Kim,Daejin; Yoon,Hoi Soo; Kim,Yeong-Seok; Lee,Hyun-Kyung; Kim,Ki Tae; Jeong,Dae Hoon; Hur,Dae Young

doi:10.3892/ijo.2014.2361

Antibody ligation of CM1 on cisplatin-exposed HeLa cells induces apoptosis through reactive oxygen species-dependent Fas ligand expression

Authors:
- Ga Bin Park
- Daejin Kim
- Hoi Soo Yoon
- Yeong-Seok Kim
- Hyun-Kyung Lee
- Ki Tae Kim
- Dae Hoon Jeong
- Dae Young Hur
View Affiliations

Affiliations: Department of Anatomy and Research Center for Woman Disease, Inje University College of Medicine, Busan 614-735, Republic of Korea, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan 614-735, Republic of Korea, Department of Obstetrics and Gynecology, Inje University Busan Paik Hospital, Busan 614-735, Republic of Korea
Published online on: March 27, 2014 https://doi.org/10.3892/ijo.2014.2361
Pages: 2016-2024

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Centrocyte/centroblast marker 1 (CM1) has been identified as a pro-apoptosis molecule on B-cell lymphoma cells as well as several types of cancer cells. In this study, we investigated its signaling mechanism in HeLa cells after treatment with cisplatin in order to potentially identify a new therapeutic target. The CM1 molecule was induced on the surface of cisplatin-exposed HeLa cells. In these cells, ligation of CM1 with anti-CM1 monoclonal antibodies inhibited cell proliferation and produced reactive oxygen species. Fas ligand (FasL) expression was upregulated without upregulating Fas in cisplatin-exposed HeLa cells after CM1 stimulation. Pretreatment with N-acetylcysteine, a pan-capase inhibitor, and ZB4, an antagonistic anti-Fas antibody, effectively inhibited the apoptotic effect triggered by CM1. CM1 ligation induced apoptosis through disruption of the mitochondrial membrane potential, decreased Bcl-2 and phosphorylated ERK expression. These findings identify CM1 as a potential new therapeutic target related to cisplatin-exposed cervical cancer.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	ZurHausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO, Xiang YB, Yeole BB, Shin HR, Shanta V, Woo ZH, Martin N, Sumitsawan Y, Sriplung H, Barboza AO, Eser S, Nene BM, Suwanrungruang K, Jayalekshmi P, Dikshit R, Wabinga H, Esteban DB, Laudico A, Bhurgri Y, Bah E and Al-Hamdan N: Cancer sur vival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 11:165–173. 2010. View Article : Google Scholar
4.	Al-Mansour Z and Verschraegen C: Locally advanced cervical cancer: what is the standard of care? Curr Opin Oncol. 22:503–512. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Eastman A: Alkylating and platinum-based agents. Curr Opin Oncol. 2:1109–1114. 1990. View Article : Google Scholar
6.	Brabec V and Kasparkova J: Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat. 5:147–161. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Djeu JY and Wei S: Clusterin and chemoresistance. Adv Cancer Res. 105:77–92. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Eastman A: Mechanisms of resistance to cisplatin. Cancer Treat Res. 57:233–249. 1991. View Article : Google Scholar : PubMed/NCBI
10.	Hur DY, Kim S, Kim YI, Min HY, Kim DJ, Lee DS, Cho D, Hwang YI, Hwang DH, Park SH, Ahn HK, Chang KY, Kim YB and Lee WJ: CM1, a possible novel activation molecule on humanlymphocytes. Immunol Lett. 74:95–102. 2000. View Article : Google Scholar : PubMed/NCBI
11.	Kim D, Hur DY, Kim YS, Lee K, Lee Y, Cho D, Kang JS, Kim YI, Hahm E, Yang Y, Yoon S, Kim S, Lee WB, Park HY, Kim YB, Hwang YI, Chang KY and Lee WJ: CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells. Hum Immunol. 63:576–587. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Kim YS, Park GB, Choi YM, Kwon OS, Song HK, Kang JS, Kim YI, Lee WJ and Hur DY: Ligation of centrocyte/centroblast marker 1 on Epstein-Barr virus-transformed B lymphocytes induces cell death in a reactive oxygen species-dependent manner. Hum Immunol. 67:795–807. 2006. View Article : Google Scholar
13.	Lee HK, Park GB, Kim YS, Song H, Broaddus VC and Hur DY: Ligation of CM1 enhances apoptosis of lung cancer cells through different mechanisms in conformity with EGFR mutation. Int J Oncol. 42:469–477. 2013.PubMed/NCBI
14.	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
15.	Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, Kim JH and Nam JH: The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol. 21:262–268. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Yunos NM, Beale P, Yu JQ and Huq F: Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 31:1131–1140. 2011.PubMed/NCBI
17.	Zhang Y, Wang C, Wang H, Wang K, Du Y and Zhang J: Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo. Cancer Lett. 304:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Zagouri F, Sergentanis TN, Chrysikos D, Filipits M and Bartsch R: Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol. 126:291–303. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T and Verschraegen C: Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 22:2166–2178. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Chen J, Adikari M, Pallai R, Parekh HK and Simpkins H: Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 61:979–987. 2008. View Article : Google Scholar
21.	Miyajima A, Nakashima J, Tachibana M, Nakamura K, Hayakawa M and Murai M: N-acetylcysteine modifies cis-dichlorodiammineplatinum-induced effects in bladder cancer cells. Jpn J Cancer Res. 90:565–570. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, Kim YT, Kim YM and Nam JH: Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 29:21–28. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer. 112:974–985. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Etter AL, Bassi I, Germain S, Delaloye JF, Tschopp J, Sordat B and Dupuis M: The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma. Gynecol Oncol. 107:14–21. 2007. View Article : Google Scholar
25.	Hougardy BM, van der Zee AG, van den Heuvel FA, Timmer T, de Vries EG and de Jong S: Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid. Gynecol Oncol. 97:353–364. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Baguley BC: Novel strategies for overcoming multidrug resistance in cancer. BioDrugs. 16:97–103. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Ikuta K, Takemura K, Kihara M, Naito S, Lee E, Shimizu E and Yamauchi A: Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Oncol Rep. 13:1229–1234. 2005.PubMed/NCBI
28.	Wu W, Wang HD, Guo W, Yang K, Zhao YP, Jiang YG and He P: Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res. 29:492010. View Article : Google Scholar : PubMed/NCBI
29.	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Wang J, Zhou JY and Wu GS: ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res. 67:11933–1141. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Wu ZZ, Sun NK, Chien KY and Chao CC: Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation. Biochem Pharmacol. 82:1630–1640. 2011. View Article : Google Scholar : PubMed/NCBI
32.	Liu WH and Chang LS: Piceatannol induces Fas and FasL up-regulation in human leukemia U937 cells via Ca²⁺/p38alpha MAPK-mediated activation of c-Jun and ATF-2 pathways. Int J Biochem Cell Biol. 42:1498–1506. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Duan SG, Cheng L, Li DJ, Zhu J, Xiong Y, Li XW and Wang SG: The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells. Dig Dis Sci. 55:2844–2852. 2010. View Article : Google Scholar : PubMed/NCBI
34.	Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J and Yi Q: Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 109:5455–5462. 2007. View Article : Google Scholar : PubMed/NCBI
35.	Filomeni G, Aquilano K, Rotilio G and Ciriolo MR: Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res. 63:5940–5949. 2003.PubMed/NCBI